SentryOne Introduces Database Monitoring Edition Targeted to Smaller Environments
7.2.2019 17:00:00 EET | Business Wire | Press release
SentryOne launched SQL Sentry Essentials, a new edition of the company’s top-rated SQL Sentry database monitoring product that provides core monitoring capabilities for up to five database targets at $995 per targeted SQL Server instance.
SQL Sentry Essentials includes the most frequently used features for monitoring, diagnosing, and optimizing SQL Server performance. This new edition is ideal for small and medium companies as well as larger organizations that need to monitor specific data systems within their environment.
“SQL Sentry Essentials is a perfect choice when you need to deploy SQL Server performance management at a small scale, or if you need enterprise capabilities but aren’t ready to build the case for an investment in a larger database performance management solution,” said Jason Hall, SentryOne VP of Product Management. “This new edition gives you the crucial information you need to get to the root of your SQL Server performance problems.”
SentryOne introduced SQL Sentry Essentials to meet the industry need for a monitoring solution that provides powerful core monitoring capabilities but excludes advanced features valued by larger enterprises.
“Everyone needs to monitor their databases, but not everyone needs all the advanced features of our flagship product, SQL Sentry,” said Andy Mallon, SentryOne Product Manager. “We’ve distilled the feature list down to the most essential monitoring capabilities, now available as SQL Sentry Essentials. This new edition is a powerful, capable solution for companies who need to monitor up to five instances, all at a very attractive price.”
SQL Sentry Essentials includes five of the most frequently used SQL Sentry features, helping data pros view essential real-time performance metrics, identify high-impact queries that are slowing performance, use proactive notifications to prevent problems, analyze SQL Server blocking and deadlocks, and view Windows resource metrics.
SentryOne customer David Klee, Heraflux Technologies Founder and Chief Architect, said that one of the features included in SQL Sentry Essentials, the Performance Analysis Dashboard, gives actionable information that helps data pros quickly identify and address problems.
“Lots of other utilities provide 'pretty' dashboards that do not provide much meaning,” Klee said. “SentryOne gives you a dashboard that presents vital performance statistics. Anything unusual jumps out at you and helps you refine how you approach that server.”
SQL Sentry Essentials is priced at US$995 per license, which can be applied to one targeted SQL Server instance, plus US$199 for annual maintenance (first year required). Subscription pricing is available at US$50 monthly (annual commitment required).
For more information, visit sentryone.com/sqlsentry-essentials.
About SentryOne
SentryOne empowers Microsoft data
professionals to build, test, document, and monitor SQL Server, Azure
SQL Database, and the Microsoft Data Platform. We help companies
accelerate performance across the data lifecycle with unmatched
scalability, best-in-industry customer support, and the most powerful
data performance management capabilities available. Our team includes a
core group of Microsoft MVPs and staff located in Charlotte, NC,
Jacksonville, FL, Salem, NH, and Dublin, Ireland. Learn more at SentryOne.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005104/en/
Contact information
Megan Keller
Communications Manager
media@sentryone.com
Erik Arvidson
Matter for SentryOne
978-518-4542
sentryone@matternow.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Frasca Pilatus PC-12 PRO Flight Training Device Receives FOCA Qualification21.4.2026 17:05:00 EEST | Press release
Frasca International, Inc., a FlightSafety International company and global leader in flight simulation, today announced that its Pilatus PC-12 PRO Flight Simulation Training Device (FSTD) received Level 2 Flight Training Device (FTD2) and Flight and Navigation Procedures Trainer (FNPT II) qualification from Switzerland’s Federal Office of Civil Aviation (FOCA). Frasca is the first to develop a PC-12 PRO training device. The device equipped with Garmin’s G3000 PRIME Avionics suite is installed at Pilatus Aircraft Ltd headquarters in Stans, Switzerland, where it will support training for the next generation of PC-12 pilots. The qualification enables pilots to complete a wide range of instruments, procedural and advanced systems training in a highly immersive environment that mirrors the capabilities of the aircraft. “The PC-12 PRO leads the way with advanced features, and we’re proud to produce a state-of-the-art simulator that allows pilots to seamlessly transition from the FTD to the
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 17:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details: frontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #7000. Session: Oral Abstract Session
Andersen Global Strengthens West Africa Platform with the Addition of Member Firm in Ghana21.4.2026 16:30:00 EEST | Press release
Andersen Global continues its expansion across Africa, with Lima Partners joining as a member firm and introducing the Andersen name in Ghana. Established in 2014 and headquartered in Accra, Andersen in Ghana is led by Managing Partner Daniel Addo Okoe. The firm provides a full range of professional services, including tax advisory, regulatory compliance, accounting and advisory, transfer pricing, payroll administration, immigration, and company secretarial services to both local and international clients operating in Ghana and the wider West African region. “Becoming a member firm of Andersen Global marks a significant milestone for our organization,” said Kwame Amporful, senior partner of Andersen in Ghana. “Our clients will benefit from enhanced cross-border capabilities while continuing to receive practical, high-quality advisory services tailored to the Ghanaian market.” “Ghana plays a vital role in facilitating cross-border trade and investment within West Africa,” added Mark L.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
